Theravance Biopharma Inc (TBPH) — Capital Reinvestment Ratio
Latest as of June 2025:
0.00x
Theravance Biopharma Inc (TBPH) has a Capital Reinvestment Ratio of 0.00x as of June 2025, meaning it reinvests 0% of its operating cash flow ($208.07 Million) in capital expenditures ($34.00K). See free cash flow generation of Theravance Biopharma Inc to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.00x
Capex / Operating Cash Flow
Operating Cash Flow
$208.07 Million
USD
Capital Expenditures
$34.00K
USD
Data as of
Jun 2025
Most recent filing
Theravance Biopharma Inc Capital Reinvestment Ratio (2025–2025)
This chart tracks Theravance Biopharma Inc's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Theravance Biopharma Inc (2025–2025)
Year-by-year Capital Reinvestment Ratio for Theravance Biopharma Inc from 2025 to 2025. For live market cap and broader valuation context, see Theravance Biopharma Inc stock valuation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.00x | $238.54 Million | $42.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow